secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-11-18T23:59:59+00:00
Accession:  0001193125-24-260923
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma reports Phase 3 BROOKLYN trial: LDL-C reduced 36.3% vs placebo at day 84, Lp(a) reduced 45.9%
--------------------------------------------------------------------------------

- LDL-C mean reduction vs placebo 36.3% at day 84 (p<0.0001), sustained at 41.5% at day 365.
- Lp(a) mean reduction vs placebo 45.9% at day 84; total LDL particles reduced 52.5% at day 180.
- Safety comparable to placebo; discontinuation rate 7.6% for obicetrapib vs 14.4% for placebo.
- Trial enrolled 354 HeFH patients; mean baseline LDL-C 123 mg/dL despite high statin use (79%) and ezetimibe (54%).
- Data presented at AHA 2024; topline from TANDEM and BROADWAY studies expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524260923/0001193125-24-260923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524260923/d840591d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-260923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer